News | December 04, 2025
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Angelini Ventures has already invested €125 million in 22 startups
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
FDA's withholding of the PRV was contrary to law because no drug product containing phenobarbital sodium was 'previously approved'
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Subscribe To Our Newsletter & Stay Updated
